Oncaidia's best practice
Wednesday, 30 July, 2008
Adelaide biotech Oncaidia [ASX: ONA] has been awarded an Asia-Pacific Frost & Sullivan Technology Innovation Award for its Apomab monoclonal antibody technology.
The award celebrates innovative work in the field of cancer diagnosis and therapy.
Oncadia was awarded it for the company's proprietary Apomab technology, which is used for detection, treatment and assessment of a range of cancers including lung, breast and prostate.
Apomab is able to identify the presence of the La protein, an autoantigen that is also overexpressed in cancer cells.
The technology promises to target cancers more accurately, reducing side effects and providing more effective treatment.
Clinical trials of Apomab are set to commence shortly.
Frost & Sullivan conduct Best Practices Awards annually. The winners are determined by industry analysts in a thorough comparison process.
Hormone therapy shifts body proteins to match gender identity
Researchers have discovered that gender-affirming hormone therapy can alter body proteins to...
Targeting 'molecular bodyguards' weakens prostate cancer cells
Research reveals that two enzymes — PDIA1 and PDIA5 — act as 'molecular...
Females found to carry a higher genetic risk of depression
An international team of scientists has discovered about twice as many genetic 'flags'...
